Iovance Biotherapeutics Enterprise Value Over EBITDA History
| IOVA Stock | USD 3.44 -0.04 -1.15% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter -2.41 | Current Value -2.41 | Quarterly Volatility 579.71981401 |
Macro event markers
Latest Iovance Biotherapeutics Enterprise Value Over EBITDA Growth Pattern
| Enterprise Value Over EBITDA | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Enterprise Value Over EBITDA Trend Statistics
The coefficient of variation for Iovance Biotherapeutics' Enterprise Value Over EBITDA stands at 400.8%, reflecting elevated dispersion relative to the mean across 15 periods. With an R-squared of 0.16, the data suggests a weak linear trend that explains limited variance.| Arithmetic Mean | -144.65 | |
| Geometric Mean | 9.25 | |
| Coefficient Of Variation | -400.77 | |
| Mean Deviation | 264.58 | |
| Median | -4.38 | |
| Standard Deviation | 579.72 | |
| Sample Variance | 336,075 | |
| Range | 2.4K | |
| R-Value | 0.40 | |
| Mean Square Error | 300,719 | |
| R-Squared | 0.16 | |
| Significance | 0.11 | |
| Slope | 46.08 | |
| Total Sum of Squares | 5.4M |
Iovance Biotherapeutics Enterprise Value Over EBITDA History
Iovance Biotherapeutics' Enterprise Value Over EBITDA is tracked from 2012 through 2026, spanning 15 reported values, moving from 47.27 to -2.53.| 2026 | -2.53 | ||
| 2025 | -2.41 | ||
| 2024 | -5.94 | ||
| 2023 | -4.38 | ||
| 2022 | -2.31 | ||
| 2021 | -8.89 | ||
| 2020 | -24.55 | ||
| 2019 | -18.15 | ||
| 2018 | -6.35 | ||
| 2017 | -4.13 | ||
| 2016 | -4.19 | ||
| 2015 | -8.97 | ||
| 2014 | -12.7 | ||
| 2013 | -3.32 | ||
| 2012 | 47.27 |
Correlation of Enterprise Value Over EBITDA With Other Accounts
The following correlation matrix compares Iovance Biotherapeutics' Enterprise Value Over EBITDA against related line items. High absolute values reflect strong historical co-movement, not a causal relationship.Click cells to compare fundamentals
Related Fundamentals
| Last Reported | End Of Year Estimate | ||
| Enterprise Value Multiple | -2.41 | -2.53 | |
| Enterprise Value | 1.7 B | 1.5 B | |
| Depreciation And Amortization | 35.9 M | 37.7 M | |
| Interest Expense | 3.4 M | 3.6 M | |
| Selling General Administrative | 152.3 M | 159.9 M | |
| Other Operating Expenses | 666.9 M | 700.2 M |
Methodology, Assumptions & Data Sources
The data below presents Iovance Biotherapeutics's Enterprise Value Over EBITDA through recent fiscal years. Sequential period comparisons surface inflection points that rolling averages can obscure. For Iovance Biotherapeutics as a Biotechnology company, Enterprise Value Over EBITDA is driven by the competitive and demand dynamics of its end markets.
Reported values for Iovance Biotherapeutics are derived from periodic company reporting and market reference feeds and standardized for analysis. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.
Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board